Articles From: Ackman Drops Push for Allergan Holder Meeting--2nd Update to Acquisition of Spansion Inc. (CODE) by Cypress Semiconductor Corp. (CY) May Not Be in Shareholders' Best Interests


2014/11/18
By Chelsey Dulaney And George Stahl Pershing Square Capital Management LP on Tuesday formally withdrew its request for a special meeting of Allergan Inc. shareholders, another indication that the firm plans to end its pursuit of the Botox maker.
Sign-up for Ackman Drops Push for Allergan Holder Meeting--2nd Update investment picks
2014/11/18
By Chelsey Dulaney And George Stahl Pershing Square Capital Management LP on Tuesday formally withdrew its request for a special meeting of Allergan Inc. shareholders, another indication that the firm plans to end its pursuit of the Botox maker.
Sign-up for Ackman Drops Push for Allergan Holder Meeting--Update investment picks
By Chelsey Dulaney Activist investor William Ackman called on Allergan Inc. to open a sale process for the Botox maker, following reports Actavis PLC has approached the company about a potential acquisition.
Sign-up for Ackman urges Allergan to open sale process, negotiate investment picks
2014/11/17
By David Benoit and Liz Hoffman Within the last month, both William Ackman and Valeant Pharmaceuticals International Inc. had sent the Allergan Inc. board letters seeking to negotiate a takeover.
Sign-up for Ackman, Valeant Can't Justify Topping Actavis Bid for Allergan investment picks
Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that the first patient has been enrolled in a Phase 3 study of CVT-301 for the treatment of OFF episodes in Parkinson’s disease (PD). OFF episodes are characterized by a re-emergence of PD symptoms such as tremor, muscle stiffness and impaired ability to move.
Sign-up for Acorda Announces Initiation of Phase 3 Trial of CVT-301 in Parkinson’s Disease investment picks
Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced it has completed its acquisition of Civitas Therapeutics and obtained global rights to CVT-301, a Phase 3 treatment candidate for OFF episodes of Parkinson’s disease.
Sign-up for Acorda Therapeutics Completes Acquisition of Civitas Therapeutics investment picks
Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that it entered into an agreement to acquire Civitas Therapeutics, a privately-held biopharmaceutical company, for $525 million in cash.
Sign-up for Acorda Therapeutics to Acquire Civitas Therapeutics investment picks
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that it will host a conference call and webcast to report its third quarter 2014 financial results on Thursday, October 30 at 8:30 a.m. ET.
Sign-up for Acorda Therapeutics to Host Conference Call to Discuss Third Quarter 2014 Financial Results on October 30, 2014 investment picks
Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that Michael Rogers, Chief Financial Officer, and Andrew Blight, Chief Scientific Officer, will present at the 26th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, December 2 at 11:00am. A live audio webcast of the presentation can be accessed under “Investor Events” in the Investor section of the Acorda website at www.acorda.com , or you may use the link: http://www.media-server.com/m/p/e2k2247a Please log in approximately 5 minutes before the scheduled time of the presentations to ensure a timely connection.
Sign-up for Acorda Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference investment picks
Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that Michael Rogers, Chief Financial Officer will present at the Credit Suisse 2014 Healthcare Conference in Phoenix on Tuesday, November 11 at 3:30pm MT.
Sign-up for Acorda Therapeutics to Present at the Credit Suisse 2014 Healthcare Conference investment picks
Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that Andrew Blight, Chief Scientific Officer, will present at the Jefferies 2014 Global Healthcare Conference in London on Wednesday, November 19 at 9:20am GMT.
Sign-up for Acorda Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference investment picks
Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that Ron Cohen, M.D., President and Chief Executive Officer will present at the Stifel 2014 Healthcare Conference on Tuesday, November 18 at 1:50pm ET.
Sign-up for Acorda Therapeutics to Present at the Stifel 2014 Healthcare Conference investment picks
By Chelsey Dulaney Acorda Therapeutics Inc. said Wednesday that it has agreed to buy fellow neurological drug maker Civitas Therapeutics for $525 million in cash, effectively putting an end to Civitas's plans to go public.
Sign-up for Acorda to buy Civitas Therapeutics for $525 million investment picks
WILMINGTON, Del.
Sign-up for Acorn Energy Announces Third Quarter and Nine Month 2014 Results investment picks
SHANGHAI , Nov.
Sign-up for Acorn International Reports Third Quarter 2014 Financial Results investment picks
In Time for the Holidays, the Leading British TV Specialist Features Collections of Agatha Christie's Poirot, Upstairs, Downstairs, Jeeves & Wooster, WWII Docs, and More *Limited DVD sets are available for gift guides SILVER SPRING, Md., Sept.
Sign-up for Acorn's Holiday Gift Sets for British TV Lovers: Mysteries, Comedies, Period Dramas and Docs investment picks
SHISHI, China , Oct.
Sign-up for Acquisition Corp. Provides Corporate Update to Shareholders investment picks
SAN DIEGO and ALISO VIEJO, Calif.
Sign-up for Acquisition of Avanir Pharmaceuticals, Inc. (AVNR) by Otsuka Pharmaceutical Co., Ltd. May Not Be in Shareholders' Best Interests investment picks
SAN DIEGO and MELVILLE, N.Y. , Nov.
Sign-up for Acquisition of ChyronHego Corporation (CHYR) by Vector Capital May Not Be in Shareholders' Best Interests investment picks
SAN DIEGO and YONKERS, N.Y. , Nov.
Sign-up for Acquisition of Hudson Valley Holding Corp. (HVB) by Sterling Bancorp (STL) May Not Be in Shareholders' Best Interests investment picks
SAN DIEGO and FREMONT, Calif., Nov.
Sign-up for Acquisition of Oplink Communications, Inc. (OPLK) by Koch Industries, Inc. May Not Be in Shareholders' Best Interests investment picks
SAN DIEGO and SUNNYVALE, Calif.
Sign-up for Acquisition of Spansion Inc. (CODE) by Cypress Semiconductor Corp. (CY) May Not Be in Shareholders' Best Interests investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Ackman Drops Push for Allergan Holder Meeting--2nd Update to Acquisition of Spansion Inc. (CODE) by Cypress Semiconductor Corp. (CY) May Not Be in Shareholders' Best Interests
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent